Scholl S M, Bascou C H, Mosseri V, Olivares R, Magdelenat H, Dorval T, Palangié T, Validire P, Pouillart P, Stanley E R
Département de Médecine Oncologique, Institut Curie, France.
Br J Cancer. 1994 Feb;69(2):342-6. doi: 10.1038/bjc.1994.62.
Serum samples from 82 patients with epithelial ovarian cancer, previously assayed for CA125, were assayed for circulating colony-stimulating factor 1 (CSF-1). An elevated CSF-1 concentration (> 450 U ml-1 or > 5.42 ng ml-1) was significantly associated with a worse survival (P = 0.02). The predictive value of raised CSF-1 levels was retained whether the first available sample for all patients (n = 82) or the first sample at the start of chemotherapy (n = 41) was considered. Mean CSF-1 levels (n = 14) dropped significantly during six courses of platinum-based chemotherapy (P = 0.02). Although an elevated CA125 concentration appeared to be a prognostic indicator in the total population (n = 82), it was not related to prognosis in the group of patients from whom samples had been drawn at the start of chemotherapy. In a Cox proportional hazards model, CSF-1, but not CA125, was significantly associated with outcome following adjustment for stage, grade and degree of surgical clearance.
对82例先前已检测过CA125的上皮性卵巢癌患者的血清样本进行循环集落刺激因子1（CSF-1）检测。CSF-1浓度升高（>450 U/ml或>5.42 ng/ml）与较差的生存率显著相关（P=0.02）。无论考虑所有患者的首个可用样本（n=82）还是化疗开始时的首个样本（n=41），CSF-1水平升高的预测价值均得以保留。在六个疗程的铂类化疗期间，14例患者的CSF-1平均水平显著下降（P=0.02）。虽然CA125浓度升高似乎是总体人群（n=82）的一个预后指标，但在化疗开始时采集样本的患者组中，它与预后无关。在Cox比例风险模型中，经调整分期、分级和手术切净程度后，CSF-1而非CA125与预后显著相关。
